What is the clinical evidence from this study?

Intervention: Reduced betaARK1 activity (betaARK1(+/-) and betaARK1(+/-)betaARKct genotypes) vs. Wild-type mice. Primary outcome: Myocardial contractile function (percent and rate of cell shortening following isoproterenol stimulation).

What question did this study set out to answer?

This study aims to analyze how varying levels of betaARK1 impact myocardial contractility in genetically modified mice.

July 1, 1998Journal of Biological ChemistryOpen Access

Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice

View Full Paper

Ask AI

Bookmark

Key result

Reduced betaARK1 activity in genetically targeted mice significantly increased myocardial contractile function and cellular responsiveness to isoproterenol compared with wild-type mice.

Why the study?

Does partial inhibition of betaARK1 activity improve myocardial contractile function in a mouse model?

Key Points

This study aims to analyze how varying levels of betaARK1 impact myocardial contractility in genetically modified mice.
Two types of genetically altered mice were used: betaARK1(+/-) and betaARK1(+/-)betaARKct.
Cardiac catheterization assessed contractile function.
Contractile parameters were measured in adult myocytes isolated from both mouse groups.
BetaARK1(+/-)betaARKct mice exhibited the highest contractile function.
Isoproterenol stimulation led to significantly greater increases in cell shortening in both betaARK1(+/-) and betaARK1(+/-)betaARKct myocytes compared to wild-type.
These findings suggest that modulation of betaARK1 activity enhances beta-adrenergic signaling.

Structured PICO

Does partial inhibition of betaARK1 activity improve myocardial contractile function in a mouse model?

Population

Genetically altered mice (betaARK1(+/-) and betaARK1(+/-)betaARKct) and wild-type mice evaluated for myocardial contractile function.

Intervention

Heterozygous betaARK1 gene ablation with or without cardiac-specific overexpression of betaARK1 COOH-terminal inhibitor peptide.

Comparator

Wild-type mice.

Outcome

Myocardial contractile function (measured via cardiac catheterization and isolated myocyte cell shortening following isoproterenol stimulation).surrogate

Partial inhibition of betaARK1 activity enhances beta-adrenergic receptor signaling and improves myocardial contractile function, suggesting betaARK1 as a potential therapeutic target in heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Positions betaARK1 as potential contractility target; leaves open human translation and clinical trials.

Cite This Study

Rockman et al. (1998) studied this question. Reduced betaARK1 activity (betaARK1(+/-) and betaARK1(+/-)betaARKct genotypes) vs. Wild-type mice was evaluated on Myocardial contractile function (percent and rate of cell shortening following isoproterenol stimulation). Reduced betaARK1 activity in genetically targeted mice significantly increased myocardial contractile function and cellular responsiveness to isoproterenol compared with wild-type mice.

synapsesocial.com/papers/6a4ee7eb19b9833b9d0b453b https://doi.org/10.1074/jbc.273.29.18180

View Full Paper

Ask AI

Bookmark

Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Keep reading

Keep reading